Sanofi presents new data on amlitelimab for atopic dermatitis

Sanofi has presented new findings on its investigational drug amlitelimab, a therapy aimed at treating atopic dermatitis, particularly for patients whose condition is not adequately controlled by topical treatments.

The new, late-breaking data were unveiled at the European Academy of Dermatology and Venerology (EADV) 2021 Virtual Congress. Amlitelimab, formerly known as KY10005, works by blocking OX40-Ligand, a key immune system regulator, to reduce inflammation. This marks the first exploration of this mechanism for moderate-to-severe atopic dermatitis.

The Phase 2a study involved 30 adult patients randomized to receive either a low or high dose of intravenous amlitelimab, administered every four weeks for a 12-week period. The treatments demonstrated significant improvements in the signs and symptoms of atopic dermatitis, including Eczema Area and Severity Index (EASI) scores. The low-dose amlitelimab group achieved an 80% improvement in EASI scores, while the high-dose group saw a 70% improvement, compared to the placebo group's 49% improvement.

The drug's safety profile was also promising, with most patients tolerating the treatment well and few serious adverse events reported. The study highlights amlitelimab's potential as a novel, first-in-class OX40-Ligand inhibitor for atopic dermatitis treatment.